These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1515096)

  • 1. Interleukin-2 increases the antibody response in patients receiving autologous intralymphatic tumor cell vaccine immunotherapy.
    Williams TW; Yanagimoto JM; Mazumder A; Wiseman CL
    Mol Biother; 1992 Jun; 4(2):66-9. PubMed ID: 1515096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
    Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.
    Maio M; Fonsatti E; Lamaj E; Altomonte M; Cattarossi I; Santantonio C; Melani C; Belli F; Arienti F; Colombo MP; Parmiani G
    Cancer Immunol Immunother; 2002 Mar; 51(1):9-14. PubMed ID: 11845255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
    Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical responses with active specific intralymphatic immunotherapy for cancer--a phase I-II trial.
    Wiseman CL; Rao VS; Kennedy PS; Presant CA; Smith JD; McKenna RJ
    West J Med; 1989 Sep; 151(3):283-8. PubMed ID: 2588564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer.
    Sivanandham M; Stavropoulos CI; Kim EM; Mancke B; Wallack MK
    Cancer Immunol Immunother; 2002 Apr; 51(2):63-71. PubMed ID: 11904730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antigenic markers of human tumor regression.
    Fareed GC; Mendiaz E; Sen A; Juillard GJ; Weisenburger TH; Totanes T
    J Biol Response Mod; 1988 Feb; 7(1):11-23. PubMed ID: 3373233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
    López-Jiménez J; Pérez-Oteyza J; Munoz A; Parra C; Villalón L; Ramos P; Maldonado M; García-Laraña J; Otheo E; Roldán E; García-Avello A; Odriozola J
    Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
    Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
    Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
    Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
    Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
    Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
    Adler A; Stein JA; Kedar E; Naor D; Weiss DW
    J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha.
    Yang SC; Owen-Schaub L; Mendiguren-Rodriguez A; Grimm EA; Hong WK; Roth JA
    J Thorac Cardiovasc Surg; 1990 Jan; 99(1):8-12; discussion 12-3. PubMed ID: 2152954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
    Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.